Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03354533Phase 1Completed

Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II

Role: lead

NCT03404856Phase 1Unknown

Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14

Role: lead

NCT03404869Phase 1Unknown

Study of ORL-1M (D-mannose) in Patients With CDG-Ib

Role: lead

NCT03269045Phase 1Completed

Study of ORL-1B in Patients With Biotinidase Deficiency

Role: lead

All 4 trials loaded